Literature DB >> 15925279

Matrix metalloproteinases and free radicals in cerebral ischemia.

K Jian Liu1, Gary A Rosenberg.   

Abstract

Cerebral ischemia induces a complex series of molecular pathways involving signaling mechanisms, gene transcription, and protein formation. The proteases and free radicals involved are important, both individually and in concert, at each of the steps in the injury cascade. Matrix metalloproteinases (MMPs) and serine proteases are essential in the breakdown of the extracellular matrix around cerebral blood vessels and neurons, and their action leads to opening of the blood-brain barrier, brain edema, hemorrhage, and cell death. Reactive oxygen and nitrogen species affect the signaling pathways that induce the enzymes, the stability of the mRNA, and their activation processes. Mice that either lack MMP genes or overexpress free radical-removing genes exhibit diminished cerebral damage after stroke. Drugs that block MMP activity, or are free radical scavengers, significantly reduce ischemic damage. Understanding the relationship between proteases and free radicals in cerebral ischemia is critical for the design of therapeutic agents aimed at controlling cell death in ischemic tissues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925279     DOI: 10.1016/j.freeradbiomed.2005.03.033

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  87 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

Review 2.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

3.  Apocynum venetum leaf extract attenuates disruption of the blood-brain barrier and upregulation of matrix metalloproteinase-9/-2 in a rat model of cerebral ischemia-reperfusion injury.

Authors:  Jun Xiang; Rui Lan; Yu-Ping Tang; Yi-Ping Chen; Ding-Fang Cai
Journal:  Neurochem Res       Date:  2012-05-17       Impact factor: 3.996

4.  Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.

Authors:  Seok Joon Won; Xian Nan Tang; Sang Won Suh; Midori A Yenari; Raymond A Swanson
Journal:  Ann Neurol       Date:  2011-10-14       Impact factor: 10.422

Review 5.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

6.  Association between IL10, IL10RA, and IL10RB SNPs and ischemic stroke with hypertension in Korean population.

Authors:  Hyun-Kyung Park; Dong Hwan Kim; Dong Hwan Yun; Ju Yeon Ban
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

Review 7.  Matrix metalloproteinases as therapeutic targets for stroke.

Authors:  Yi Yang; Gary A Rosenberg
Journal:  Brain Res       Date:  2015-04-25       Impact factor: 3.252

8.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

Review 9.  Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury.

Authors:  Xing-miao Chen; Han-sen Chen; Ming-jing Xu; Jian-gang Shen
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

10.  Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study.

Authors:  Sergio Amaro; Víctor Obach; Alvaro Cervera; Xabier Urra; Manuel Gómez-Choco; Anna M Planas; Angel Chamorro
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.